The C-terminal amide of native amylin is preserved, as is the N-terminal disulfide-bridged ring structure (Cys2Cys7), both of which are required for full amylin receptor efficacy
It is also a highly effective option for patients who cannot tolerate the gastrointestinal side effects of gut-directed peptides
A qualified medical professional will take the time to understand your unique health profile and goals, ensuring your treatment plan is tailored to you
When to call your provider Within 3-5 days: No bowel movement for 5+ days despite using Miralax or other osmotic laxative Severe abdominal pain or distension Inability to pass gas Vomiting, especially if it tastes or smells fecal Within 1-2 weeks: Constipation not improving after 2 weeks of consistent dietary changes plus Miralax Blood in stool (bright red or dark/tarry) Severe pain during bowel movements Unintended weight loss beyond expected from the medication At your next scheduled visit: Mild persistent constipation that's manageable but bothersome Questions about whether to escalate dose given current constipation Interest in prescription motility agents The threshold for calling is lower if you have a history of bowel obstruction, diverticulitis, inflammatory bowel disease, or prior abdominal surgery
Other warnings Intensive therapy for megaloblastic anemia may result in hypokalemia, thrombocytosis, and life-threatening complications
Current research has found that ferroptosis caused by the downregulation of the Nrf2/HO-1/GPX4 pathway is closely associated with diminished ovarian reserve (Niu et al., 2023